{{Rsnum
|rsid=17183814
|Gene=SCN2A
|Chromosome=2
|position=165295879
|Orientation=plus
|GMAF=0.073
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SCN2A
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.0 | 15.0 | 85.0
| HCB | 3.0 | 25.2 | 71.9
| JPT | 0.0 | 10.0 | 90.0
| YRI | 0.0 | 8.8 | 91.2
| ASW | 0.0 | 9.1 | 90.9
| CHB | 3.0 | 25.2 | 71.9
| CHD | 5.5 | 22.9 | 71.6
| GIH | 0.0 | 34.3 | 65.7
| LWK | 0.0 | 3.7 | 96.3
| MEX | 1.7 | 29.3 | 69.0
| MKK | 0.0 | 0.6 | 99.4
| TSI | 0.0 | 12.7 | 87.3
| HapMapRevision=28
}}{{PMID Auto
|PMID=19694741
|Title=Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population
|OA=1
}}

{{GET Evidence
|gene=SCN2A
|aa_change=Arg19Lys
|aa_change_short=R19K
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs17183814
|overall_frequency_n=627
|overall_frequency_d=10758
|overall_frequency=0.0582822
|n_genomes=6
|n_genomes_annotated=0
|n_haplomes=6
|n_articles=0
|n_articles_annotated=0
|gene_in_genetests=Y
|pph2_score=0.956
|genetests_testable=Y
|nblosum100=-3
|autoscore=3
|n_web_uneval=10
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}